HEMATOLOGY/ONCOLOGY AND STEM CELL THERAPY
The Journal of the King Faisal Specialist Hospital & Research Centre

AUTHOR INFORMATION PACK

TABLE OF CONTENTS

- Description p.1
- Abstracting and Indexing p.1
- Editorial Board p.1
- Guide for Authors p.4

DESCRIPTION

Hematology Oncology and Stem Cell Therapy is an international, peer-reviewed, open access journal that provides a vehicle for publications of high-quality clinical as well as basic science research reports in hematology and oncology. The contents of the journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors. The journal prioritizes publication of original research articles but also would give consideration for brief reports, review articles, special communications, and unique case reports. It also offers a special section for clinically relevant images that provide an important educational value.

ABSTRACTING AND INDEXING

Directory of Open Access Journals (DOAJ)
PubMed/Medline
Scopus

EDITORIAL BOARD

Editor-in-Chief
Mahmoud Aljurf, Director, Adult HSCT Program; Deputy Director, Oncology Center; Scientific Director EMBMT; King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Associate Editors
G. Abou-Alfa, Memorial Sloan-Kettering Cancer Center, New York, USA
M. Al Shabanah, Head, Radiation Oncology, Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
U. Gergis, Medical Director, Hematology/Oncology for Global Services, Leukemia & Bone Marrow Transplant Service, Weill Cornell Medical College, New York, USA
M.A. Kharfan-Dabaja, Dept. of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA

Editorial Board
A.A. Abbadi, Hematology and Oncology, University of Jordan, Amman, Jordan
H. Abdel-Razeq, King Hussein Cancer Center, Amman, Jordan
A. Ahmed, Department of Adult Hematology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia

ISSN: 1658-3876
D. Ajarim, Dept. of Hematology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
M. Al Shabanah, Head, Radiation Oncology, Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
H. Al Zahrai, Division of Adult Hematology and Hematopoietic, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
M. Alabdualy, Consultant and Head of pediatric urology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
A. Albadawi, Dept. of Obstetrics and Gynecology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
K. Almoqaddam, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
A. Alkofide, Division of Adult Hematology and Hematopoietic, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
F. Almohareb, Division of Adult Hematology and Hematopoietic, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
A. Almseed, Adult Hematology / Bone Marrow Transplantation, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Jeddah, Saudi Arabia
M. Arat, Istanbul Bilgi University, Istanbul, Turkey
A. Ayas, Division of Adult Hematology and Hematopoietic, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
G. W. Basak, Department of Hematology, Medical University of Warsaw, Warsaw, Poland
A. Bazarbachi, Dept. of Internal Medicine, American University of Beirut (AUB), Lebanon, USA
S. Bazarbashi, Division of Adult Hematology and Hematopoietic, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
M.A. Bekadja, Dept. of Cell Therapy and Hematology, The Algerian society of Hematology and Blood Transfusion, Oran, Algeria
S. Benekroun, Department of Hematology, Children's Hospital, Casablanca, Morocco
T.V. Binh, Blood Transfusion & Hematology Hospital, Ho Chi Minh, Viet Nam
M. Chandy, Tata Medical Centre, kolkata, India
P.M. Chen, National Yang-Ming University, Taipei, Turkey
S. Chiattoni, Department of Hematology, Santa Casa School of Medicine of Sào Paulo, São Paulo, Brazil
A. El Quesar, Dept. of Onco-Hematology, Centre Hospitalier Universitaire Ibn Rochdi, Casablanca, Morocco
H. El Solh, Department of Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
T. Elhassen, Oncology Centre, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
G. Gan, Department of Medicine, The Adult Hematology Unit, University of Malaya Specialist Centre (UMSC), Kuala Lumpur, Malaysia
A. Ghavamzadeh, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
D. Gomez Almague, Universidad Autónoma de Nuevo León, Nuevo Leon, Mexico
A. Hamidieh, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
S. Issaragrisil, Faculty of Medicine, Siriraj Hospital, Division of Hematology, Mahidol University, Bangkok, Thailand
A. Jazieh, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia
Y.M. Khafaga, Dept. of Biostatistics, Epidemiology and Scientific Computing, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
Y. Kodera, School of Medicine, Aichi Medical University, Aichi, Japan
M. Koh, Department of Hematology/Stem Cell Transplantation, Singapore General Hospital, Singapore
B. Labar, Department of Hematology, Klinicki bolnicki centar Zagreb, Zagreb, Croatia
S. Ladeb, Department of Hematology, Centre National de Greffe de Moelle Osseuse(CNGMO), Tunis, Tunisia
J. Lee, Division of Hematology, Department of Internal Medicine, Catholic University of Korea, Seoul, The Republic of Korea
P. Lu, Hebei Yanda Lu Daopei Hospital, Beijing, China
H. Mahmoud, Dept. of Medical Oncology, Cairo University, Giza, Egypt
A. Mohiuddin, Dept. of Hematology and Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia
N. Novitzky, Dept. of Medicine and Pathology, University of Cape Town, Rondebosch, South Africa
T. Othman, Dept. of Hematology, Centre National de Greffe de Moelle Osseuse(CNGMO), Tunis, Tunisia
R. Pasquini, Faculdade de Medicina, Universidade Federal do Paraná (UFPR), Curitiba, Brazil
M. Patel, Dept. of Medicine, University of Witwatersrand, Johannesburg, South Africa
J. Pereira, Dept. of Hematology- Oncology, Pontificia Universidad Católica de Chile, Santiago, Chile
G. Ruiz-Arlegues, Center for Hematology and Internal Medicine, Monterrey, Mexico
T. Shamsi, Nat. Institute Of Blood Disease & Bone Marrow Transplantation, University of Karachi, Karachi, Pakistan
O. Srivastava, Dept. of Hematology, The Tamil Nadu Dr. M.G.R. Medical University, Chennai, India
T. Wu, Dept. of Bone Marrow Transplantation, Beijing Daopei Hospital, Beijing, China

Publication office staff
Amal Al-Ghammas
GUIDE FOR AUTHORS

INTRODUCTION
The Editors of Hematology/Oncology and Stem Cell Therapy welcome contributions from our readers. We seek high quality clinical and basic research reports in hematology and oncology, including the use of stem cell therapy in treating hematologic diseases and malignancies, from throughout the world, but particularly from countries whose research might be underrepresented in the current medical literature. Priority will be given to manuscripts that have a greater public health impact or that highlight unique geographic distributions or behaviors of blood diseases or cancer. We publish original research reports, brief communications, reviews, editorials, special communications, letters and case reports.

Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address

All necessary files have been uploaded:
Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print
Graphical Abstracts / Highlights files (where applicable)
Supplemental files (where applicable)

Further considerations
• Manuscript has been 'spell checked' and 'grammar checked'
• All references mentioned in the Reference List are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Internet)
• A competing interests statement is provided, even if the authors have no competing interests to declare
• Journal policies detailed in this guide have been reviewed
• Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

BEFORE YOU BEGIN
Ethics in publishing
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.

Studies in humans and animals
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.
All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.

**Conflict of interest**

All authors must disclose any financial and personal relationships with other people or organisations that could inappropriately influence (bias) their work. Examples of potential conflicts of interest include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. See also https://www.elsevier.com/conflictsofinterest.

Please complete and upload the Conflict of Interest and Author Declaration form with your manuscript. Inclusion of this form is mandatory.

**Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

**Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

**Contributors**

Each author is required to declare his or her individual contribution to the article: all authors must have materially participated in the research and/or article preparation, so roles for all authors should be described. The statement that all authors have approved the final article should be true and included in the disclosure.

**Changes to authorship**

Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

**Clinical trial results**

In line with the position of the International Committee of Medical Journal Editors, the journal will not consider results posted in the same clinical trials registry in which primary registration resides to be prior publication if the results posted are presented in the form of a brief structured (less than 500 words) abstract or table. However, divulging results in other circumstances (e.g., investors’ meetings) is discouraged and may jeopardise consideration of the manuscript. Authors should fully disclose all posting in registries of results of the same or closely related work.
Reporting clinical trial

All randomised controlled trials submitted for publication should include a completed Consolidated Standards of Reporting Trials (CONSORT) flow chart. Please refer to the CONSORT statement website at http://www.consort-statement.org for more information and the STROBE statement for observational studies (see http://www.equator-network.org/). For human gene nomenclature, see the instructions at the back of the journal. This journal has adopted the proposal from the International Committee of Medical Journal Editors (ICMJE) which require, as a condition of consideration for publication of clinical trials, registration in a public trials registry. Trials must register at or before the onset of patient enrolment. The clinical trial registration number should be included at the end of the abstract of the article. For this purpose, a clinical trial is defined as any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects of health outcomes. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example drugs, surgical procedures, devices, behavioural treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration. Further information can be found at http://www.icmje.org.

Copyright

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (for more information on this and copyright, see https://www.elsevier.com/copyright). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Author rights

As an author you (or your employer or institution) have certain rights to reuse your work. For more information on author rights please see https://www.elsevier.com/copyright.

Elsevier supports responsible sharing

Find out how you can share your research published in Elsevier journals.

Open access

Every peer-reviewed research article appearing in this journal will be published open access. This means that the article is universally and freely accessible via the internet in perpetuity, in an easily readable format immediately after publication. The author does not have any publication charges for open access. The King Faisal Specialist Hospital & Research Centre will pay to make the article open access.

A CC user license manages the reuse of the article (see https://www.elsevier.com/openaccesslicenses). All articles will be published under the following license:

Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

Elsevier Researcher Academy

Researcher Academy is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

Language and language services

Please write your text in good English (American or British usage is accepted, but not a mixture of these). All accepted manuscripts will be edited prior to publication.
Submission
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

Submit your article
Please submit your article via http://ees.elsevier.com/hemoncstem/

Referees
Please submit the names and institutional e-mail addresses of several potential referees. For more details, visit our Support site. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.

PREPARATION
Peer review
This journal operates a double blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review.

Double-blind review
This journal uses double-blind review, which means the identities of the authors are concealed from the reviewers, and vice versa. More information is available on our website. To facilitate this, please include the following separately:

Title page (with author details): This should include the title, authors' names, affiliations, acknowledgements and any Declaration of Interest statement, and a complete address for the corresponding author including an e-mail address.
Blinded manuscript (no author details): The main body of the paper (including the references, figures, tables and any acknowledgements) should not include any identifying information, such as the authors' names or affiliations.

Use of word processing software
It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

Words limit
Word count limits are 3500 words for original research reports, 2000 for brief communications, case reports, and mini-reviews, and 750 for letters. The word count should include references listed at the end of the article.
Introduction
State the objectives of the work and provide adequate background to highlight the significance of your study, question asked, and hypothesis tested. Also, Avoid a detailed literature survey or a summary of the results.

Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Theory/calculation
A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

Results
The results section should always begin with text that reports the key results without interpretation, in an orderly and logical sequence, using both text and illustrative materials (Tables and Figures). Statistical analysis for your data should appear either in text (usually parenthetically), related Tables, or Figures (in the legend or in footnote under the Table or Figure).

Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
• Author names and affiliations. Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.
• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Abstract
A concise and factual abstract is required which contains no more than 250 words. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Math formulae
Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

Artwork
Image manipulation
Whilst it is accepted that authors sometimes need to manipulate images for clarity, manipulation for purposes of deception or fraud will be seen as scientific ethical abuse and will be dealt with accordingly. For graphical images, this journal is applying the following policy: no specific feature within an image may be enhanced, obscured, moved, removed, or introduced. Adjustments of brightness, contrast, or color balance are acceptable if and as long as they do not obscure or eliminate any information present in the original. Nonlinear adjustments (e.g. changes to gamma settings) must be disclosed in the figure legend.

Electronic artwork
General points
- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format. Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
- EPS (or PDF): Vector drawings, embed all used fonts.
TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.

Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

Reference
List references in consecutive numerical order (the order of citation in the manuscript, and not alphabetically). Once a reference is cited, all subsequent citations should be to the original number. References to material on the Internet should include the date of access. Manuscripts with incorrectly formatted citations will be returned to the author for correction. The author is responsible for the accuracy and completeness of the references and for their correct textual citation. In-text reference numbers should be superscripted and placed after the period (not in parentheses), as at the end of this sentence. The reference style required by the journal will be applied to the published version by Elsevier.

Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue
Please ensure that the words ‘this issue’ are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:

Reference to a journal publication with an article number:

Reference to a book:

Reference to a chapter in an edited book:

Reference to a website:

Reference to a dataset:

Note shortened form for last page number. e.g., 51–9, and that for more than 6 authors the first 6 should be listed followed by 'et al.' For further details you are referred to 'Uniform Requirements for Manuscripts submitted to Biomedical Journals' (J Am Med Assoc 1997;277:927–34) (see also Samples of Formatted References).

Journal abbreviations source
Journal names should be abbreviated according to the List of Title Word Abbreviations.

Supplementary material
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

AFTER ACCEPTANCE

Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.
If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.
We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will be published.

Nomenclature for Human Genes
HEMONC_image.jpg

© Copyright 2018 Elsevier | https://www.elsevier.com